| P2093 | author name string | Brad S Kahl | |
| | Moniba Nazeef | |
| P2860 | cites work | Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma | Q22306235 |
| | The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 |
| | A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project | Q28239256 |
| | A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma | Q28254924 |
| | Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial | Q28286064 |
| | Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma | Q30371806 |
| | Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma | Q33364244 |
| | Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma | Q33372761 |
| | Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma | Q33393436 |
| | Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation | Q33405812 |
| | A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma | Q33418456 |
| | Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma | Q33420889 |
| | Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era | Q34568868 |
| | Treatment of older patients with mantle-cell lymphoma. | Q34641279 |
| | Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group | Q34725141 |
| | Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways | Q36254627 |
| | Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499 | Q37065959 |
| | Lenalidomide for the treatment of B-cell malignancies | Q37088809 |
| | Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma | Q37482527 |
| | Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells | Q37564773 |
| | Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). | Q37636965 |
| | Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo | Q39831203 |
| | High dose chlorambucil in the treatment of lymphoid malignancies | Q44854220 |
| | Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. | Q45008293 |
| | Outcome of deferred initial therapy in mantle-cell lymphoma | Q46135838 |
| | lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells | Q46482921 |
| | Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. | Q53099728 |
| | The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma | Q57279573 |
| | Multiple lymphomatous polyposis of the gastrointestinal tract: prospective clinicopathologic study of 31 cases. Groupe D'étude des Lymphomes Digestifs | Q71933824 |
| | Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma | Q78842144 |
| | Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS | Q82107735 |
| | Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen | Q82749255 |
| P433 | issue | 6 | |
| P921 | main subject | mantle cell lymphoma | Q268713 |
| P304 | page(s) | 29 | |
| P577 | publication date | 2015-06-01 | |
| P1433 | published in | Current Treatment Options in Oncology | Q3510796 |
| P1476 | title | Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation | |
| P478 | volume | 16 | |